Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Sarcoma and Rare Cancers 2023 | Novel approaches in treating soft tissue sarcoma with immunotherapy

Zuzana Střížová • 13 Mar 2023
ESMO Sarcoma and Rare Cancers 2023
Sarcoma Antibodies Checkpoint Inhibitors

Zuzana Střížová, MD, PhD, Charles University, Prague, Czech Republic, comments on enhancing the efficacy of immunotherapies in treating soft tissue sarcoma. Many immune checkpoint inhibitors are ineffective due to low expression of PD-(L)1. However, the presence of LAG-3 and TIM3 may provide novel strategies to target soft tissue sarcomas. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Zuzana Střížová

2:07
Overcoming resistance to checkpoint inhibitors in soft tissue sarcomas
Zuzana Střížová • 13 Mar 2023

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals